Condition

Hodgkin Lymphoma

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 30 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials30

Recruiting7

Common interventions25

Lead sponsors shown15

Clinical trials

30 shown

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding AreasNCT07285044 · 2025-12-18

Genetic Markers of Susceptibility to Chemotherapy-induced Ovarian Damage in Cancer Patients Undergoing Ovarian Biopsy for Cryopreservation.NCT07270679 · 2025-07-23

New Approaches for the Diagnosis of Lymphoma and Multicentric Castleman DiseaseNCT07793006 · 2025-03-17

Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot TrialNCT06580002 · 2024-12-02

A Phase 1 of CTX-8371 in Patients With Advanced MalignanciesNCT06150664 · 2024-03-19

Early Ageing During Therapy in AYA Cancer PatientsNCT05062707 · 2022-02-10

Familial Investigations of Childhood Cancer PredispositionNCT03050268 · 2017-04-06

Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO TrialNCT07576725 · 2026-12-01

NOT_YET_RECRUITING

Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced CardiotoxicityNCT07838649 · 2026-11-01

NOT_YET_RECRUITING

Integrated Actionable Aging Assessment for Cancer Patients PilotNCT05871008 · 2024-03-01

ACTIVE_NOT_RECRUITING

Frequency of Pulmonary Toxicity in Patients Treated for Hodgkin LymphomaNCT06761599 · 2024-02-18

ACTIVE_NOT_RECRUITING

Lymphoma Patients Undergoing Mediastinal Radiotherapy in the Era of Modern ChemoradiationNCT03969693 · 2023-05-01

NOT_YET_RECRUITING

Improving Exercise Capacity With a Tailored Physical Activity InterventionNCT05595577 · 2023-03-01

ACTIVE_NOT_RECRUITING

Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or LymphomasNCT05565417 · 2022-11-28

ACTIVE_NOT_RECRUITING

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)NCT05508867 · 2022-10-18

The BurnAlong Pilot Study for Adolescent and Young Adult Cancer SurvivorsNCT05131815 · 2022-07-25

Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer SurvivorsNCT07259304 · 2021-11-24

ACTIVE_NOT_RECRUITING

Lung Screening in People Cured of Hodgkin LymphomaNCT04986189 · 2021-08-01

Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic CancersNCT04072393 · 2021-01-15

SARS-CoV-2 Donor-Recipient Immunity TransferNCT04666025 · 2020-09-23

Developing Lung Cancer Screening in Hodgkin Lymphoma Survivors: a Qualitative StudyNCT04396119 · 2020-02-11

Genetic Predictors of Efficiency and Safety of ICIs in Patients With Different Malignancies (ICIPRESIST-0519)NCT04025424 · 2019-06-15

Improving Exercise Capacity With Tailored Physical Activity in Lymphoma & Breast Cancer Patients Undergoing TxNCT03923504 · 2019-05-10

SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or LymphomasNCT03894618 · 2019-03-26

Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or LymphomaNCT03096782 · 2017-10-13

⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's LymphomaNCT03107663 · 2017-06-19

Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)NCT02684292 · 2016-05-23

BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and HematologyNCT01660776 · 2012-06-07

124I-FIAU Imaging in EBV and KSHV Associated CancersNCT00982449 · 2010-12-01

Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer PatientsNCT05974410

Common interventions

Leading sponsors

Merck Sharp & Dohme LLC 2 The Christie NHS Foundation Trust 2 Washington University School of Medicine 2 AVM Biotechnology Inc 1 Cedars-Sinai Medical Center 1 Chang Gung Memorial Hospital 1 City of Hope Medical Center 1 Compass Therapeutics 1 Fred Hutchinson Cancer Center 1 ImaginAb, Inc. 1 Immunitas Therapeutics 1 Indiana University 1 IRCCS Azienda Ospedaliero-Universitaria di Bologna 1 M.D. Anderson Cancer Center 1 Mayo Clinic 1

Trial status mix

COMPLETED12

RECRUITING7

ACTIVE_NOT_RECRUITING5

NOT_YET_RECRUITING3

AVAILABLE1

TERMINATED1

UNKNOWN1

Phase mix

NA8

PHASE26

PHASE15

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.